avapro has been researched along with Osteoporosis in 2 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetes-associated osteoporosis is mainly caused by the formation and accumulation of advanced glycation end products (AGEs)." | 1.48 | Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. ( Chen, H; Cheng, YZ; Wang, JY; Wang, LT; Yang, L; Yang, SL; Ye, M; Zhang, H; Zhuo, XY, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, CJ | 1 |
| Yang, X | 1 |
| Wang, SH | 1 |
| Wu, XT | 1 |
| Mao, Y | 1 |
| Shi, JW | 1 |
| Fan, YB | 1 |
| Sun, LW | 1 |
| Cheng, YZ | 1 |
| Yang, SL | 1 |
| Wang, JY | 1 |
| Ye, M | 1 |
| Zhuo, XY | 1 |
| Wang, LT | 1 |
| Chen, H | 1 |
| Zhang, H | 1 |
| Yang, L | 1 |
2 other studies available for avapro and Osteoporosis
| Article | Year |
|---|---|
Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products.
Topics: Animals; Bone and Bones; Glycation End Products, Advanced; Irbesartan; Osteoporosis; Rats; Reactive | 2023 |
Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomechanical Phenomena; Biphenyl Compounds; Cell | 2018 |